There Were Twice As Many Reverse Mergers As IPOs During the First Half of 2005

Gateway Research, an affiliate of The Wall Street Transcript, announced the release date for the publication of its Special Report on Reverse Mergers and SPACs which will be September 28.

David Wanetick, Managing Director of Gateway Research, said, "There is much more reverse merger and SPAC activity than IPO activity. However, it is very difficult to collect and synthesize information on reverse mergers and SPAC transactions. We are very proud of our research team, spearheaded by Richard Tullo, which compiled statistics on over 100 recent reverse mergers and SPACs as well as composed over 100 pages of insightful analysis about the reverse merger process."

This report delves into detail about all relevant aspects of reverse mergers and SPACs including:

-- The average capital raises by reverse mergers and SPACs.

-- The average market capitalizations of reverse merged companies and SPACs.

-- An analysis of why there is such a high rate of de-listings of reverse mergers and SPACs.

-- An analysis of rising shell prices.

-- The definition of clean shells.

-- A discussion of the trend and implications of the profusion of Chinese companies doing reverse mergers.

-- A discussion of the pros and cons of raising capital contemporaneously with executing reverse merger transactions versus raising capital after the transactions.

-- An analysis of legal requirements relating to Rule 144, 8-K disclosure filing requirements, states concerns regarding exempting registration of SPACs as well as 505 and 506 Reg. D exemptions.

-- An analysis of the trading liquidity characteristics of stocks traded in various venues.

A preview of this report is available at the Vertical Pulse blog (www.verticalpulse.com) and the entire 150 page report will be released at The Wall Street Transcript's Reverse Mergers / Forward Momentum Conference in New York City on September 28. (www.twst.com/conferences)

MicroMed Announces Closing of Reverse Merger and Financing

MicroMed Technology, Inc., a leader in miniaturized implantable ventricular assist technology, is pleased to announce that it has completed its previously announced merger with a wholly-owned subsidiary of Salmon Express, Inc. (OTCBB:SXPI.OB). The combined company has been renamed MicroMed Cardiovascular, Inc. and will have its shares publicly quoted on the OTC Bulletin Board. In connection with the merger, MicroMed also completed an equity financing through a private placement of $5 million of its common stock by Hunter World Markets, Inc. of Beverly Hills, California.

"The DeBakey VAD(R) is the result of years of dedication and perseverance to launch a generation of miniaturized technology designed to help thousands of victims of heart failure. The merger and concurrent financing will enable us to move forward as a public company, giving us greater access to the capital markets and more exposure for our DeBakey VAD technology," said Travis E. Baugh, President and CEO. "We believe that MicroMed is well positioned with a fully implantable VAD technology designed to support both adults and children with heart failure, a devastating and spiraling disease."